Endurance Wealth Management’s West Pharmaceutical WST Stock Holding History

Endurance Wealth Management’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$228K	Hold	595	–	–	0.03%	185
2023 Q1	$206K	Hold	595	–	–	0.03%	192
2022 Q4	$140K	Hold	595	–	–	0.02%	222
2022 Q3	$146K	Hold	595	–	–	0.02%	216
2022 Q2	$180K	Hold	595	–	–	0.03%	197
2022 Q1	$244K	Hold	595	–	–	0.03%	190
2021 Q4	$279K	Hold	595	–	–	0.03%	189
2021 Q3	$253K	Hold	595	–	–	0.03%	199
2021 Q2	$213K	Hold	595	–	–	0.02%	213
2021 Q1	$168K	Buy	595 +554	+1,351%	+$159K	0.02%	230
2020 Q4	$12K	Hold	41	–	–	﹤0.01%	478
2020 Q3	$11K	Buy	+41	New	+$10.8K	﹤0.01%	462

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DCP

Durable Capital Partners Bethesda, Maryland $10.3B AUM 29.04% 1-Year Est. Return

Endurance Wealth Management's WST Position: Q2 2023 in Review

Endurance Wealth Management held its West Pharmaceutical (WST) position steady in Q2 2023 at 595 shares worth $228K. The position accounts for 0.03% of the portfolio, ranked #185.

Endurance Wealth Management first reported a position in WST in Q3 2020 and has held it in 12 quarters since. The position peaked at $279K in Q4 2021. 734 funds tracked by Wall St. Rank hold WST as of Q2 2023.

Endurance Wealth Management held 595 shares of West Pharmaceutical worth $228K as of Q2 2023.
Endurance Wealth Management left its West Pharmaceutical share count unchanged in Q2 2023.
West Pharmaceutical made up 0.03% of Endurance Wealth Management's portfolio in Q2 2023, its #185 holding.
Endurance Wealth Management first reported a position in West Pharmaceutical in Q3 2020 and has held it in 12 quarters since.
Endurance Wealth Management's West Pharmaceutical position peaked at $279K in Q4 2021.
734 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2023.

Based on Endurance Wealth Management's 13F filing for Q2 2023, filed 9 Aug 2023.